

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/511,489
Filing Date	December 16, 2004
First Named Inventor	Maria V. SERGEEVA
Art Unit	1734- 1624
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2029.00

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number – Kind Code ² (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/DR/	1	US-4,053,638	10-11-77	Litchfield et al.	
↓	2	US-4,083,974	04-11-87	Turi	
↓	3	US-4,339,440	07-13-82	Bajusz et al.	
↓	4	US-5,918,568	07-06-99	Gjerlov	
↓	5	US-6,110,908	08-29-00	Guthery	
↓	6	US-6,143,790	11/07/00	Hallinan et al.	
↓	7	US-6,159,706	12-12-00	Shepard	
↓	8	US-6,245,750 B1	06-12-01	Shepard	
↓	9	US-6,339,151 B1	01-15-02	Shepard et al.	
↓	10	US-6,448,058 B1	09-10-02	Patel et al.	
↓	11	US-6,613,879 B1	09-02-03	Firestone et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
/DR/	12	WO 98/13059 A	04-02-98	Bristol-Myers Squibb Company		
↓	13	WO 99/08110	02-18-99	NewBiotics, Inc.		
↓	14	WO 99/37753	07-29-99	NewBiotics, Inc.		
↓	15	WO 01/07454 A1	02-01-01	NewBiotics, Inc.		
↓	16	WO 02/089739 A2	11-14-02	NewBiotics, Inc.		
↓	17	WO 2004/43400 A2	05-27-04	NewBiotics, Inc.		

Examiner's
Signature

/Deepak Rao/


Date
Considered

09/19/2007

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.



Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/511,489
Filing Date	December 16, 2004
First Named Inventor	Maria V. SERGEEVA
Art Unit	-1734 1624
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2029.00

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
/DR/	1	APFEL, C. et al. "Hydroxamic Acid Derivatives as Potent Peptide Deformylase Inhibitors and Antibacterial Agents" <i>J. Med. Chem.</i> (2000) 43:2324-2331	
	2	APFEL, C.M. et al. "Peptide Deformylase as an Antibacterial Drug Target: Assays for Detection of Its Inhibition in <i>Escherichia coli</i> Cell Homogenates and Intact Cells" <i>Anti. Agents and Chemo.</i> (April 2001a) 45(4):1053-1057	
	3	APFEL, C.M. et al. "Peptide Deformylase as an Antibacterial Drug Target: Target Validation and Resistance Development" <i>Anti. Agents and Chemo.</i> (April 2001b) 45(4):1058-1064	
	4	BECKER, A. et al. "Iron Center, Substrate Recognition and Mechanism of Peptide Deformylase" <i>Nat. Struct. Biol.</i> (Dec. 1998) 5(12):1053-1058	
	5	BODUSZEK, B. "Synthesis of Novel Phosphonopeptides Derived from Pyridylmethylphosphonate Diphenyl Esters" <i>Casereact.</i> (2001) 136:279691	
	6	CHAN, M.K. et al. "Crystal Structure of the <i>Escherichia coli</i> Peptide Deformylase" <i>Biochem.</i> (1997) 36:13904-13909	
	7	CHEN, D.Z. et al. "Actinonin, a Naturally Occurring Antibacterial Agent, is a Potent Deformylase Inhibitor" <i>Biochem.</i> (2000) 39(6):1256-1262	
	8	CLEMENTS, J.M. et al. "Antibiotic Activity and Characterization of BB-3497, a Novel Peptide Deformylase Inhibitor" <i>Anti. Agents and Chemo.</i> (Feb. 2001) 45(2):563-570	
	9	de GROOT, F.M.H. et al. "Synthesis and Biological Evaluation of Novel Prodrugs of Anthracyclines for Selective Activation by the Tumor-Associated Protease Plasmin" <i>J. Med. Chem.</i> (1999) 42(25):5277-5283	
	10	de GROOT, F.M.H. et al. "Synthesis and Biological Evaluation of 2'-Carbamate-Linked and 2'-Carbonate-Linked Prodrugs of Paclitaxel: Selective Activation by the Tumor-Associated Protease Plasmin" <i>J. Med. Chem.</i> (2000) 43:3093-3102	
	11	DUBOWCHIK, G.M. and R.A. FIRESTONE "Cathepsin B-Sensitive Dipeptide Prodrugs. 1. A Model Study of Structural Requirements for Efficient Release of Doxorubicin" <i>Bioorg. & Med. Chem. Letts.</i> (1998) 8(23):3341-3346	
	12	DURAND, D.J. et al. "Peptide Aldehyde Inhibitors of Bacterial Peptide Deformylases" <i>Arch. Biochem. & Biophysics</i> (July 15, 1999) 367(2):297-302	
	13	GIGLIONE, C. et al. "Peptide Deformylase as a Target for New Generation, Broad Spectrum Antimicrobial Agents" <i>Mol. Microbiol.</i> (2000a) 36(6):1197-1205	
	14	GIGLIONE, C. et al. "Identification of Eukaryotic Peptide Deformylases Reveals Universality of N-Terminal Protein Processing Mechanisms" <i>EMBO J.</i> (2000b) 19(21):5916-5929	

Examiner's
Signature

/Deepak Rao/

Date

Considered

09/19/2007


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B-PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **2** of **2****Complete if Known**

Application Number	10/511,489
Filing Date	December 16, 2004
First Named Inventor	Maria V. SERGEEVA
Art Unit	4734- 1624
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2029.00

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
/DR/	15	HAO, B. et al. "Structural Basis for the Design of Antibiotics Targeting Peptide Deformylase" <i>Biochem.</i> (1999) 38(15):4712-4719	
	16	HU, Y.J. et al. "H-phosphonate Derivatives as Novel Peptide Deformylase Inhibitors" <i>Bioorg. Med. Chem. Letts.</i> (1998) 8(18):2479-2482	
	17	HUNTINGTON, K.M. et al. "Synthesis and Antibacterial Activity of Peptide Deformylase Inhibitors" <i>Biochem.</i> (2000) 39(15):4543-4551	
	18	JAYASEKERA, M.M.K. et al. "Novel Nonpeptidic Inhibitors of Peptide Deformylase" <i>Arch. Biochem. & Biophys.</i> (Sept. 15, 2000) 381(2):313-316	
	19	LACKEY, D.B. et al. "Enzyme-Catalyzed Therapeutic Agent (ECTA) Design: Activation of the Antitumor ECTA Compound NB 1011 by Thymidylate Synthase" <i>Biochem. Pharm.</i> (2001) 61:179-189	
	20	LIU, X.-J. et al. "Synthesis and Anticancer Activities of New 5-fluorouracil-1-yl Phosphonotriptides" <i>Casreact.</i> (2002) 138:106974	
	21	MEINNEL, T. "Vers une conception rationnelle de nouveaux agents antibactériens" <i>Pathol. Biol.</i> (Oct. 1999) 47(8):780-783	X
	22	MEINNEL, T. et al. "Methionine as Translation Start Signal: A Review of the Enzymes of the Pathway in <i>Escherichia coli</i> " <i>Biochimie.</i> (1993) 75(12):1061-1075	
	23	RAGUSA, S. et al. "Control of Peptide Deformylase Activity by Metal Cations" <i>J. Mol. Biol.</i> (1998) 280:515-523	
	24	RAJAGOPALAN, P.T.R. et al. "Purification, Characterization, and Inhibition of Peptide Deformylase from <i>Escherichia Coli</i> " <i>Biochem.</i> (1997) 36(45):13910-13918	
	25	RAJAGOPALAN, P.T.R. and D. PEI "Oxygen-Mediated Inactivation of Peptide Deformylase" <i>J. Biol. Chem.</i> (Aug. 28, 1998) 273(35):22305-22310	
	26	WEI, Y. and D. PEI "Continuous Spectrophotometric Assay of Peptide Deformylase" <i>Anal. Biochem.</i> (1997) 250(1):29-34	
	27	WEI, Y. et al. "Identification of a Potent Peptide Deformylase Inhibitor from a Rationally Designed Combinatorial Library" <i>J. Comb. Chem.</i> (2000a) 2(6):650-657 Year: 2000	
	28	WEI, Y. and D. PEI "Activation of Antibacterial Prodrugs by Peptide Deformylase" <i>Bioorg. Med. Chem. Letts.</i> (2000b) 10(10):1073-1076 Year: 2000	
	29	International Search Report dated October 15, 2003 for PCT/US2003/011981	

Examiner's
Signature

/Deepak Rao/

Date

Considered 09/19/2007

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: May 3, 2006 (use as many sheets as necessary)				Application Number	10/511,489
				Filing Date	4/17/2003
				First Named Inventor	Maria V Sergeeva
				Group Art Unit	1624
				Examiner Name	Deepak R. Rao
Sheet	1	of	2	Attorney Docket Number	060925-2900

U.S. PATENT DOCUMENTS

[illegible]

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Application Document		Name of Patentee or Applicant of Cited Document	Filing Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	/Deepak Rao/	Date Considered	09/19/2007
-----------------------	--------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/511,489
Date Submitted: May 3, 2006		Filing Date	4/17/2003
(use as many sheets as necessary)		First Named Inventor	Maria V Sergeeva
		Group Art Unit	1624
		Examiner Name	Deepak R. Rao
		Attorney Docket Number	060925-2900
Sheet	2	of	2

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
/DR/	6	CARL, P.L. et al. "A Novel Connector Linkage Applicable in Prodrug Design" <i>J. Med. Chem.</i> (May, 1981) 34(5):479-480	
/DR/	7	deGROOT, F.M.H. et al. "Elongated Multipl Electronic Cascade and Cyclization Spacer Systems in Activatable Anticancer Prodrugs for Enhanced Drug Release" <i>J. Org. Chem.</i> (2001) 66:8815-8830	
/DR/	8	NICULESCU-DUVAZ, D. et al. "Self-Immolative Nitrogen Mustard Prodrugs for Suicide Gene Therapy" <i>J. Med. Chem.</i> (1998) 41:5297-5309	
/DR/	9	TOKI, B.E. et al. "Protease-Mediated Fragmentation of <i>p</i> -Amidobenzyl Ethers: A New Strategy for the Activation of Anticancer Prodrugs" <i>J. Org. Chem.</i> (2002) 67:1866-1872	

Examiner Signature	/Deepak Rao/	Date Considered	09/19/2007
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: July 19, 2006

(Use as many sheets as necessary)

Complete if Known

Application Number	10/511,489
Filing Date	4/17/2003
First Named Inventor	Maria V Sergeeva
Group Art Unit	1624
Examiner Name	Deepak R. Rao
Attorney Docket Number	060925-2900

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Application Document		Name of Patentee or Applicant of Cited Document	Filing Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
/DR/	1		WO 02/07780		Newbiotics, Inc.	01/31/2002		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
/DR/	2	Li et al. "NB2001, a novel broad spectrum antibiotic with enhanced potency towards beta-lactamase-producing bacterial strains" <i>Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy</i> (2001) vol. 41, pg. 221 XP008064922	

Examiner
Signature

/Deepak Rao/

Date
Considered

09/19/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/511,489
				Filing Date	4/17/2003
				First Named Inventor	Maria V Sergeeva
				Group Art Unit	1624
Date Submitted: July 19, 2006				Examiner Name	Deepak R. Rao
(use as many sheets as necessary)				Attorney Docket Number	060925-2900
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
/DR/	3	Sergeeva et al. "Plasma stability of antibacterial N-formyldipeptide esters acting via peptide deformylase" <i>Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy</i> (2002) vol. 42, pg. 196 XP008064894	
/DR/	4	Sergeeva et al. "Plasma stability of antibacterial N-formyldipeptide esters acting via peptide deformylase" <i>Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy</i> (2002) vol. 42, pg. 196 XP008064883	
/DR/	5	Supplementary Partial European Search Report dated 6/20/06 EP03721752	

Examiner Signature	/Deepak Rao/	Date Considered	09/19/2007
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.